Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18.
暂无分享,去创建一个
E. Braunwald | C. Cannon | A. Kirtane | N. Rifai | D. Morrow | C. McCabe | Jacqueline Buros | C. Gibson | K. Ray | C. Gibson | C. Mccabe
[1] E. Braunwald,et al. Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial. , 2006, The American journal of cardiology.
[2] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[3] R. Giugliano,et al. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. , 2005, Journal of the American College of Cardiology.
[4] R. Heine,et al. Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. , 2004, Archives of internal medicine.
[5] Tzung-Dau Wang,et al. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. , 2004, The American journal of cardiology.
[6] E. Topol,et al. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. , 2004, European heart journal.
[7] S. Jo,et al. Nitric Oxide Production and Regulation of Endothelial Nitric-oxide Synthase Phosphorylation by Prolonged Treatment with Troglitazone , 2004, Journal of Biological Chemistry.
[8] P. Libby,et al. Soluble CD40L: Risk Prediction After Acute Coronary Syndromes , 2003, Circulation.
[9] Petr Jarolim,et al. Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic Patients: A Novel Target of Thiazolidinediones , 2003, Circulation.
[10] M. Roden,et al. Diabetic LDL triggers apoptosis in vascular endothelial cells. , 2003, Diabetes.
[11] W. Koenig,et al. Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease , 2003, Circulation.
[12] S. Verma,et al. Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone. , 2003, Journal of molecular and cellular cardiology.
[13] E. Antman,et al. Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes , 2003, Circulation.
[14] S. Devaraj,et al. C-Reactive Protein Increases Plasminogen Activator Inhibitor-1 Expression and Activity in Human Aortic Endothelial Cells: Implications for the Metabolic Syndrome and Atherothrombosis , 2003, Circulation.
[15] J. W. Box,et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study , 2000 .
[16] A. Hata,et al. Advanced glycation end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages. , 2000, Biochemical and biophysical research communications.
[17] R. Cannon. Cardiovascular benefit of cholesterol-lowering therapy: does improved endothelial vasodilator function matter? , 2000, Circulation.
[18] A. Skene,et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. , 2000, Circulation.
[19] J. W. Box,et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. , 2000, European heart journal.
[20] P. Ridker,et al. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. , 1999, The American journal of cardiology.
[21] E. Antman,et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.
[22] KlasMalmberg,et al. Glycometabolic State at Admission: Important Risk Marker of Mortality in Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Infarction , 1999 .
[23] Paul J Thornalley. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. , 1998, Cellular and molecular biology.
[24] Hiroshi Yamamoto,et al. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells , 1998, Diabetologia.
[25] G. Shen,et al. Influence of glycation on LDL-induced generation of fibrinolytic regulators in vascular endothelial cells. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[26] E. Antman,et al. C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy , 1998 .
[27] G. Remuzzi,et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. , 1998, The Journal of clinical investigation.
[28] E. Antman,et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. , 1998, Journal of the American College of Cardiology.
[29] F. Numano,et al. The Effect of Glucose and Advanced Glycosylation End Products on IL‐6 Production by Human Monocytes , 1994, Annals of the New York Academy of Sciences.
[30] S. Cobbe. Thrombolysis in myocardial infarction , 1994, BMJ.